Specialty medical injectable drug program updates: Hemophilia Treatment Centers
New specialty medical injectable guidelines and requirements announced.
- All states
- Products and services
Please review the following information to determine changes to our specialty medical injectable drug programs.
Beginning Aug. 1, 2021, Hemophilia Treatment Centers (HTCs) seeking coverage under a member’s medical benefit for self-administered medications, such as Hemlibra or factor products, used to treat bleeding disorders must be contracted with a specific HTC fee schedule that allows them to dispense bleeding disorder medications for UnitedHealthcare Commercial members. HTCs not contracted with an HTC-specific fee schedule will need to transition members self-administering these products to a participating specialty pharmacy or an HTC already contracted with an HTC fee schedule when their current prior authorization expires.
For more information, please contact your broker or UnitedHealthcare representative.
More updates for your clients
New releases, updates and notifications for a broad spectrum of UnitedHealthcare products and services.